nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Mercaptopurine—hematologic cancer	0.345	0.754	CbGbCtD
Brimonidine—AOX1—Methotrexate—hematologic cancer	0.113	0.246	CbGbCtD
Brimonidine—Clonidine—SLC22A1—hematologic cancer	0.00105	0.774	CrCbGaD
Brimonidine—Clonidine—ABCB1—hematologic cancer	0.000305	0.225	CrCbGaD
Brimonidine—Bradycardia—Epirubicin—hematologic cancer	6.94e-05	0.000155	CcSEcCtD
Brimonidine—Headache—Alitretinoin—hematologic cancer	6.94e-05	0.000154	CcSEcCtD
Brimonidine—Nausea—Thalidomide—hematologic cancer	6.91e-05	0.000154	CcSEcCtD
Brimonidine—Dyspepsia—Triamcinolone—hematologic cancer	6.9e-05	0.000154	CcSEcCtD
Brimonidine—Rash—Ifosfamide—hematologic cancer	6.9e-05	0.000154	CcSEcCtD
Brimonidine—Dermatitis—Ifosfamide—hematologic cancer	6.89e-05	0.000153	CcSEcCtD
Brimonidine—Dizziness—Irinotecan—hematologic cancer	6.87e-05	0.000153	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—hematologic cancer	6.84e-05	0.000152	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—hematologic cancer	6.83e-05	0.000152	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—hematologic cancer	6.81e-05	0.000152	CcSEcCtD
Brimonidine—Syncope—Prednisone—hematologic cancer	6.81e-05	0.000152	CcSEcCtD
Brimonidine—Asthenia—Cisplatin—hematologic cancer	6.77e-05	0.000151	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—hematologic cancer	6.77e-05	0.000151	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—hematologic cancer	6.76e-05	0.000151	CcSEcCtD
Brimonidine—Fatigue—Triamcinolone—hematologic cancer	6.76e-05	0.00015	CcSEcCtD
Brimonidine—Rash—Vincristine—hematologic cancer	6.73e-05	0.00015	CcSEcCtD
Brimonidine—Dermatitis—Vincristine—hematologic cancer	6.72e-05	0.00015	CcSEcCtD
Brimonidine—Pain—Triamcinolone—hematologic cancer	6.7e-05	0.000149	CcSEcCtD
Brimonidine—Headache—Vincristine—hematologic cancer	6.69e-05	0.000149	CcSEcCtD
Brimonidine—Loss of consciousness—Prednisone—hematologic cancer	6.67e-05	0.000149	CcSEcCtD
Brimonidine—Hypotension—Betamethasone—hematologic cancer	6.65e-05	0.000148	CcSEcCtD
Brimonidine—Hypotension—Dexamethasone—hematologic cancer	6.65e-05	0.000148	CcSEcCtD
Brimonidine—Nausea—Carmustine—hematologic cancer	6.64e-05	0.000148	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—hematologic cancer	6.61e-05	0.000147	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—hematologic cancer	6.6e-05	0.000147	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—hematologic cancer	6.58e-05	0.000147	CcSEcCtD
Brimonidine—Nausea—Alitretinoin—hematologic cancer	6.58e-05	0.000146	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—hematologic cancer	6.57e-05	0.000146	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—hematologic cancer	6.57e-05	0.000146	CcSEcCtD
Brimonidine—Hypertension—Prednisone—hematologic cancer	6.55e-05	0.000146	CcSEcCtD
Brimonidine—Rash—Irinotecan—hematologic cancer	6.55e-05	0.000146	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—hematologic cancer	6.55e-05	0.000146	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—hematologic cancer	6.55e-05	0.000146	CcSEcCtD
Brimonidine—Dermatitis—Irinotecan—hematologic cancer	6.55e-05	0.000146	CcSEcCtD
Brimonidine—Headache—Irinotecan—hematologic cancer	6.51e-05	0.000145	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—hematologic cancer	6.51e-05	0.000145	CcSEcCtD
Brimonidine—Nausea—Ifosfamide—hematologic cancer	6.5e-05	0.000145	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.48e-05	0.000144	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.48e-05	0.000144	CcSEcCtD
Brimonidine—Myalgia—Prednisone—hematologic cancer	6.46e-05	0.000144	CcSEcCtD
Brimonidine—Arthralgia—Prednisone—hematologic cancer	6.46e-05	0.000144	CcSEcCtD
Brimonidine—Anxiety—Prednisone—hematologic cancer	6.44e-05	0.000143	CcSEcCtD
Brimonidine—Insomnia—Dexamethasone—hematologic cancer	6.43e-05	0.000143	CcSEcCtD
Brimonidine—Insomnia—Betamethasone—hematologic cancer	6.43e-05	0.000143	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—hematologic cancer	6.42e-05	0.000143	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.42e-05	0.000143	CcSEcCtD
Brimonidine—Paraesthesia—Betamethasone—hematologic cancer	6.39e-05	0.000142	CcSEcCtD
Brimonidine—Paraesthesia—Dexamethasone—hematologic cancer	6.39e-05	0.000142	CcSEcCtD
Brimonidine—Discomfort—Prednisone—hematologic cancer	6.39e-05	0.000142	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—hematologic cancer	6.39e-05	0.000142	CcSEcCtD
Brimonidine—Rash—Gemcitabine—hematologic cancer	6.38e-05	0.000142	CcSEcCtD
Brimonidine—Dermatitis—Gemcitabine—hematologic cancer	6.38e-05	0.000142	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—hematologic cancer	6.37e-05	0.000142	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—hematologic cancer	6.37e-05	0.000142	CcSEcCtD
Brimonidine—Erythema—Methotrexate—hematologic cancer	6.34e-05	0.000141	CcSEcCtD
Brimonidine—Headache—Gemcitabine—hematologic cancer	6.34e-05	0.000141	CcSEcCtD
Brimonidine—Nausea—Vincristine—hematologic cancer	6.34e-05	0.000141	CcSEcCtD
Brimonidine—Flushing—Epirubicin—hematologic cancer	6.33e-05	0.000141	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—hematologic cancer	6.33e-05	0.000141	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—hematologic cancer	6.33e-05	0.000141	CcSEcCtD
Brimonidine—Hypersensitivity—Prednisolone—hematologic cancer	6.28e-05	0.00014	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—hematologic cancer	6.26e-05	0.000139	CcSEcCtD
Brimonidine—Dyspepsia—Betamethasone—hematologic cancer	6.26e-05	0.000139	CcSEcCtD
Brimonidine—Dyspepsia—Dexamethasone—hematologic cancer	6.26e-05	0.000139	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—hematologic cancer	6.21e-05	0.000138	CcSEcCtD
Brimonidine—Asthenia—Etoposide—hematologic cancer	6.2e-05	0.000138	CcSEcCtD
Brimonidine—Oedema—Prednisone—hematologic cancer	6.2e-05	0.000138	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—hematologic cancer	6.19e-05	0.000138	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—hematologic cancer	6.17e-05	0.000137	CcSEcCtD
Brimonidine—Nausea—Irinotecan—hematologic cancer	6.17e-05	0.000137	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—hematologic cancer	6.16e-05	0.000137	CcSEcCtD
Brimonidine—Infection—Prednisone—hematologic cancer	6.16e-05	0.000137	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—hematologic cancer	6.15e-05	0.000137	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.14e-05	0.000137	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.14e-05	0.000137	CcSEcCtD
Brimonidine—Fatigue—Dexamethasone—hematologic cancer	6.13e-05	0.000137	CcSEcCtD
Brimonidine—Fatigue—Betamethasone—hematologic cancer	6.13e-05	0.000137	CcSEcCtD
Brimonidine—Pruritus—Etoposide—hematologic cancer	6.12e-05	0.000136	CcSEcCtD
Brimonidine—Shock—Prednisone—hematologic cancer	6.1e-05	0.000136	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—hematologic cancer	6.09e-05	0.000136	CcSEcCtD
Brimonidine—Pain—Dexamethasone—hematologic cancer	6.08e-05	0.000135	CcSEcCtD
Brimonidine—Pain—Betamethasone—hematologic cancer	6.08e-05	0.000135	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—hematologic cancer	6.08e-05	0.000135	CcSEcCtD
Brimonidine—Nervous system disorder—Prednisone—hematologic cancer	6.08e-05	0.000135	CcSEcCtD
Brimonidine—Tachycardia—Prednisone—hematologic cancer	6.05e-05	0.000135	CcSEcCtD
Brimonidine—Skin disorder—Prednisone—hematologic cancer	6.02e-05	0.000134	CcSEcCtD
Brimonidine—Nausea—Gemcitabine—hematologic cancer	6.01e-05	0.000134	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—hematologic cancer	5.98e-05	0.000133	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—hematologic cancer	5.98e-05	0.000133	CcSEcCtD
Brimonidine—Rash—Cisplatin—hematologic cancer	5.95e-05	0.000132	CcSEcCtD
Brimonidine—Dermatitis—Cisplatin—hematologic cancer	5.94e-05	0.000132	CcSEcCtD
Brimonidine—Erythema—Epirubicin—hematologic cancer	5.94e-05	0.000132	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—hematologic cancer	5.9e-05	0.000131	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—hematologic cancer	5.86e-05	0.00013	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—hematologic cancer	5.86e-05	0.00013	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—hematologic cancer	5.81e-05	0.000129	CcSEcCtD
Brimonidine—Hypersensitivity—Triamcinolone—hematologic cancer	5.78e-05	0.000129	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—hematologic cancer	5.73e-05	0.000127	CcSEcCtD
Brimonidine—Dizziness—Etoposide—hematologic cancer	5.72e-05	0.000127	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—hematologic cancer	5.7e-05	0.000127	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—hematologic cancer	5.69e-05	0.000127	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.64e-05	0.000126	CcSEcCtD
Brimonidine—Dizziness—Prednisolone—hematologic cancer	5.64e-05	0.000126	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—hematologic cancer	5.64e-05	0.000126	CcSEcCtD
Brimonidine—Asthenia—Triamcinolone—hematologic cancer	5.63e-05	0.000125	CcSEcCtD
Brimonidine—Nausea—Cisplatin—hematologic cancer	5.6e-05	0.000125	CcSEcCtD
Brimonidine—Insomnia—Prednisone—hematologic cancer	5.6e-05	0.000125	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—hematologic cancer	5.6e-05	0.000125	CcSEcCtD
Brimonidine—Paraesthesia—Prednisone—hematologic cancer	5.56e-05	0.000124	CcSEcCtD
Brimonidine—Pruritus—Triamcinolone—hematologic cancer	5.55e-05	0.000123	CcSEcCtD
Brimonidine—Cough—Methotrexate—hematologic cancer	5.54e-05	0.000123	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—hematologic cancer	5.53e-05	0.000123	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—hematologic cancer	5.49e-05	0.000122	CcSEcCtD
Brimonidine—Dyspepsia—Prednisone—hematologic cancer	5.45e-05	0.000121	CcSEcCtD
Brimonidine—Rash—Etoposide—hematologic cancer	5.45e-05	0.000121	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—hematologic cancer	5.45e-05	0.000121	CcSEcCtD
Brimonidine—Headache—Etoposide—hematologic cancer	5.42e-05	0.000121	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—hematologic cancer	5.4e-05	0.00012	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—hematologic cancer	5.4e-05	0.00012	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—hematologic cancer	5.4e-05	0.00012	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—hematologic cancer	5.38e-05	0.00012	CcSEcCtD
Brimonidine—Rash—Prednisolone—hematologic cancer	5.38e-05	0.00012	CcSEcCtD
Brimonidine—Dermatitis—Prednisolone—hematologic cancer	5.37e-05	0.00012	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.36e-05	0.000119	CcSEcCtD
Brimonidine—Fatigue—Prednisone—hematologic cancer	5.34e-05	0.000119	CcSEcCtD
Brimonidine—Headache—Prednisolone—hematologic cancer	5.34e-05	0.000119	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—hematologic cancer	5.34e-05	0.000119	CcSEcCtD
Brimonidine—Syncope—Epirubicin—hematologic cancer	5.32e-05	0.000119	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—hematologic cancer	5.25e-05	0.000117	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—hematologic cancer	5.22e-05	0.000116	CcSEcCtD
Brimonidine—Dizziness—Triamcinolone—hematologic cancer	5.18e-05	0.000115	CcSEcCtD
Brimonidine—Cough—Epirubicin—hematologic cancer	5.18e-05	0.000115	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—hematologic cancer	5.18e-05	0.000115	CcSEcCtD
Brimonidine—Infection—Methotrexate—hematologic cancer	5.14e-05	0.000115	CcSEcCtD
Brimonidine—Nausea—Etoposide—hematologic cancer	5.13e-05	0.000114	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—hematologic cancer	5.13e-05	0.000114	CcSEcCtD
Brimonidine—Asthenia—Dexamethasone—hematologic cancer	5.1e-05	0.000114	CcSEcCtD
Brimonidine—Asthenia—Betamethasone—hematologic cancer	5.1e-05	0.000114	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—hematologic cancer	5.08e-05	0.000113	CcSEcCtD
Brimonidine—Nausea—Prednisolone—hematologic cancer	5.06e-05	0.000113	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—hematologic cancer	5.05e-05	0.000113	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—hematologic cancer	5.05e-05	0.000113	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—hematologic cancer	5.05e-05	0.000113	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—hematologic cancer	5.04e-05	0.000112	CcSEcCtD
Brimonidine—Pruritus—Betamethasone—hematologic cancer	5.03e-05	0.000112	CcSEcCtD
Brimonidine—Pruritus—Dexamethasone—hematologic cancer	5.03e-05	0.000112	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—hematologic cancer	5.03e-05	0.000112	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.02e-05	0.000112	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—hematologic cancer	4.99e-05	0.000111	CcSEcCtD
Brimonidine—Rash—Triamcinolone—hematologic cancer	4.94e-05	0.00011	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—hematologic cancer	4.94e-05	0.00011	CcSEcCtD
Brimonidine—Dermatitis—Triamcinolone—hematologic cancer	4.94e-05	0.00011	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—hematologic cancer	4.93e-05	0.00011	CcSEcCtD
Brimonidine—Headache—Triamcinolone—hematologic cancer	4.91e-05	0.000109	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—hematologic cancer	4.85e-05	0.000108	CcSEcCtD
Brimonidine—Oedema—Epirubicin—hematologic cancer	4.85e-05	0.000108	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—hematologic cancer	4.84e-05	0.000108	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—hematologic cancer	4.83e-05	0.000107	CcSEcCtD
Brimonidine—Infection—Epirubicin—hematologic cancer	4.81e-05	0.000107	CcSEcCtD
Brimonidine—Cough—Doxorubicin—hematologic cancer	4.79e-05	0.000107	CcSEcCtD
Brimonidine—Shock—Epirubicin—hematologic cancer	4.77e-05	0.000106	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—hematologic cancer	4.75e-05	0.000106	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—hematologic cancer	4.74e-05	0.000106	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—hematologic cancer	4.73e-05	0.000105	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.72e-05	0.000105	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—hematologic cancer	4.71e-05	0.000105	CcSEcCtD
Brimonidine—Dizziness—Betamethasone—hematologic cancer	4.7e-05	0.000105	CcSEcCtD
Brimonidine—Dizziness—Dexamethasone—hematologic cancer	4.7e-05	0.000105	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—hematologic cancer	4.68e-05	0.000104	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—hematologic cancer	4.68e-05	0.000104	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—hematologic cancer	4.68e-05	0.000104	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—hematologic cancer	4.68e-05	0.000104	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—hematologic cancer	4.66e-05	0.000104	CcSEcCtD
Brimonidine—Nausea—Triamcinolone—hematologic cancer	4.66e-05	0.000104	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—hematologic cancer	4.65e-05	0.000104	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.64e-05	0.000103	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—hematologic cancer	4.62e-05	0.000103	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—hematologic cancer	4.62e-05	0.000103	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—hematologic cancer	4.6e-05	0.000102	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—hematologic cancer	4.57e-05	0.000102	CcSEcCtD
Brimonidine—Hypersensitivity—Prednisone—hematologic cancer	4.56e-05	0.000102	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—hematologic cancer	4.56e-05	0.000101	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—hematologic cancer	4.53e-05	0.000101	CcSEcCtD
Brimonidine—Rash—Betamethasone—hematologic cancer	4.49e-05	9.99e-05	CcSEcCtD
Brimonidine—Rash—Dexamethasone—hematologic cancer	4.49e-05	9.99e-05	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—hematologic cancer	4.48e-05	9.98e-05	CcSEcCtD
Brimonidine—Dermatitis—Dexamethasone—hematologic cancer	4.48e-05	9.98e-05	CcSEcCtD
Brimonidine—Dermatitis—Betamethasone—hematologic cancer	4.48e-05	9.98e-05	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.47e-05	9.95e-05	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—hematologic cancer	4.46e-05	9.94e-05	CcSEcCtD
Brimonidine—Headache—Betamethasone—hematologic cancer	4.46e-05	9.92e-05	CcSEcCtD
Brimonidine—Headache—Dexamethasone—hematologic cancer	4.46e-05	9.92e-05	CcSEcCtD
Brimonidine—Infection—Doxorubicin—hematologic cancer	4.45e-05	9.92e-05	CcSEcCtD
Brimonidine—Asthenia—Prednisone—hematologic cancer	4.45e-05	9.9e-05	CcSEcCtD
Brimonidine—Pain—Methotrexate—hematologic cancer	4.43e-05	9.86e-05	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.41e-05	9.83e-05	CcSEcCtD
Brimonidine—Shock—Doxorubicin—hematologic cancer	4.41e-05	9.82e-05	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—hematologic cancer	4.4e-05	9.79e-05	CcSEcCtD
Brimonidine—Pruritus—Prednisone—hematologic cancer	4.38e-05	9.76e-05	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—hematologic cancer	4.38e-05	9.76e-05	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—hematologic cancer	4.38e-05	9.74e-05	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—hematologic cancer	4.36e-05	9.7e-05	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—hematologic cancer	4.35e-05	9.69e-05	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—hematologic cancer	4.32e-05	9.62e-05	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—hematologic cancer	4.31e-05	9.59e-05	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—hematologic cancer	4.27e-05	9.5e-05	CcSEcCtD
Brimonidine—Nausea—Betamethasone—hematologic cancer	4.23e-05	9.41e-05	CcSEcCtD
Brimonidine—Nausea—Dexamethasone—hematologic cancer	4.23e-05	9.41e-05	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—hematologic cancer	4.19e-05	9.33e-05	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.18e-05	9.31e-05	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—hematologic cancer	4.18e-05	9.3e-05	CcSEcCtD
Brimonidine—Pain—Epirubicin—hematologic cancer	4.14e-05	9.23e-05	CcSEcCtD
Brimonidine—Dizziness—Prednisone—hematologic cancer	4.1e-05	9.12e-05	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.08e-05	9.09e-05	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—hematologic cancer	4.06e-05	9.03e-05	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—hematologic cancer	4.03e-05	8.96e-05	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—hematologic cancer	4e-05	8.9e-05	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—hematologic cancer	3.99e-05	8.87e-05	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—hematologic cancer	3.95e-05	8.79e-05	CcSEcCtD
Brimonidine—Rash—Prednisone—hematologic cancer	3.91e-05	8.7e-05	CcSEcCtD
Brimonidine—Dermatitis—Prednisone—hematologic cancer	3.9e-05	8.69e-05	CcSEcCtD
Brimonidine—Headache—Prednisone—hematologic cancer	3.88e-05	8.64e-05	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.87e-05	8.62e-05	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—hematologic cancer	3.87e-05	8.61e-05	CcSEcCtD
Brimonidine—Pain—Doxorubicin—hematologic cancer	3.83e-05	8.54e-05	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—hematologic cancer	3.81e-05	8.49e-05	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—hematologic cancer	3.72e-05	8.27e-05	CcSEcCtD
Brimonidine—Nausea—Prednisone—hematologic cancer	3.68e-05	8.19e-05	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—hematologic cancer	3.66e-05	8.16e-05	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—hematologic cancer	3.57e-05	7.95e-05	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—hematologic cancer	3.48e-05	7.74e-05	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—hematologic cancer	3.43e-05	7.63e-05	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—hematologic cancer	3.42e-05	7.62e-05	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—hematologic cancer	3.3e-05	7.35e-05	CcSEcCtD
Brimonidine—Rash—Methotrexate—hematologic cancer	3.26e-05	7.27e-05	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—hematologic cancer	3.26e-05	7.26e-05	CcSEcCtD
Brimonidine—Headache—Methotrexate—hematologic cancer	3.24e-05	7.22e-05	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—hematologic cancer	3.22e-05	7.16e-05	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—hematologic cancer	3.2e-05	7.13e-05	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—hematologic cancer	3.17e-05	7.06e-05	CcSEcCtD
Brimonidine—Nausea—Methotrexate—hematologic cancer	3.08e-05	6.85e-05	CcSEcCtD
Brimonidine—Rash—Epirubicin—hematologic cancer	3.06e-05	6.8e-05	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—hematologic cancer	3.05e-05	6.8e-05	CcSEcCtD
Brimonidine—Headache—Epirubicin—hematologic cancer	3.04e-05	6.76e-05	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—hematologic cancer	2.96e-05	6.6e-05	CcSEcCtD
Brimonidine—Nausea—Epirubicin—hematologic cancer	2.88e-05	6.41e-05	CcSEcCtD
Brimonidine—Rash—Doxorubicin—hematologic cancer	2.83e-05	6.29e-05	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—hematologic cancer	2.82e-05	6.29e-05	CcSEcCtD
Brimonidine—Headache—Doxorubicin—hematologic cancer	2.81e-05	6.25e-05	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—hematologic cancer	2.66e-05	5.93e-05	CcSEcCtD
Brimonidine—ADRA2A—Hemostasis—TGFB1—hematologic cancer	1.41e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FOXO1—hematologic cancer	1.41e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—hematologic cancer	1.41e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRB—hematologic cancer	1.41e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CREB1—hematologic cancer	1.41e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTM1—hematologic cancer	1.4e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NCOR1—hematologic cancer	1.4e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—hematologic cancer	1.39e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT1—hematologic cancer	1.39e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRA—hematologic cancer	1.38e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JAK1—hematologic cancer	1.38e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRKCG—hematologic cancer	1.38e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2RA—hematologic cancer	1.38e-05	0.000151	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—hematologic cancer	1.38e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL2—hematologic cancer	1.37e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6R—hematologic cancer	1.37e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—hematologic cancer	1.37e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—hematologic cancer	1.37e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—hematologic cancer	1.36e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	1.35e-05	0.000148	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—hematologic cancer	1.34e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFB—hematologic cancer	1.33e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—JAK2—hematologic cancer	1.31e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—hematologic cancer	1.31e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAP2K1—hematologic cancer	1.31e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TSC2—hematologic cancer	1.3e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GRB2—hematologic cancer	1.3e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—hematologic cancer	1.3e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFA—hematologic cancer	1.3e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—hematologic cancer	1.29e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2RA—hematologic cancer	1.29e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—hematologic cancer	1.28e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—hematologic cancer	1.28e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KITLG—hematologic cancer	1.28e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—hematologic cancer	1.27e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGFR3—hematologic cancer	1.25e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT5A—hematologic cancer	1.25e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	1.25e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFB—hematologic cancer	1.24e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—hematologic cancer	1.24e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK14—hematologic cancer	1.24e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN2B—hematologic cancer	1.24e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3R1—hematologic cancer	1.23e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ESR1—hematologic cancer	1.22e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TSC2—hematologic cancer	1.22e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—hematologic cancer	1.21e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—hematologic cancer	1.2e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FN1—hematologic cancer	1.2e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD86—hematologic cancer	1.2e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—JAK2—hematologic cancer	1.19e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CREBBP—hematologic cancer	1.19e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFKBIA—hematologic cancer	1.19e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BAD—hematologic cancer	1.19e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES1—hematologic cancer	1.18e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH1—hematologic cancer	1.18e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NCOR1—hematologic cancer	1.17e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGFR3—hematologic cancer	1.17e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—hematologic cancer	1.16e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	1.16e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CSF2—hematologic cancer	1.16e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK14—hematologic cancer	1.16e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD80—hematologic cancer	1.15e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	1.15e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—hematologic cancer	1.15e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	1.15e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	1.14e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	1.14e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	1.14e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ESR1—hematologic cancer	1.14e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	1.13e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	1.13e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—hematologic cancer	1.13e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	1.12e-05	0.000123	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—hematologic cancer	1.12e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FN1—hematologic cancer	1.12e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	1.12e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	1.12e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—hematologic cancer	1.11e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—hematologic cancer	1.11e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BAD—hematologic cancer	1.11e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFKBIA—hematologic cancer	1.11e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	1.1e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH1—hematologic cancer	1.1e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	1.09e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	1.08e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD80—hematologic cancer	1.08e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—hematologic cancer	1.07e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—hematologic cancer	1.07e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—hematologic cancer	1.07e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	1.07e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	1.07e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3R1—hematologic cancer	1.07e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	1.07e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTPN11—hematologic cancer	1.05e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	1.05e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	1.04e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	1.04e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	1.03e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	1.03e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	1.02e-05	0.000112	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	1.02e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	1.01e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	1.01e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	1.01e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	1e-05	0.00011	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	1e-05	0.00011	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	9.97e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	9.95e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	9.89e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	9.87e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—hematologic cancer	9.84e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—hematologic cancer	9.82e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	9.67e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CREBBP—hematologic cancer	9.67e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	9.54e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	9.5e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	9.5e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	9.44e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	9.4e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	9.35e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	9.27e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	9.24e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	9.22e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	9.17e-06	0.0001	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	9.11e-06	9.99e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	9.09e-06	9.96e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	9.05e-06	9.92e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—hematologic cancer	9.05e-06	9.92e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	9.04e-06	9.9e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	9e-06	9.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	9e-06	9.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	8.92e-06	9.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	8.91e-06	9.77e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	8.81e-06	9.65e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	8.81e-06	9.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	8.74e-06	9.57e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	8.72e-06	9.56e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	8.72e-06	9.56e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	8.72e-06	9.56e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	8.66e-06	9.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	8.66e-06	9.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	8.57e-06	9.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—hematologic cancer	8.5e-06	9.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	8.49e-06	9.3e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	8.46e-06	9.27e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	8.41e-06	9.22e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	8.35e-06	9.15e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	8.3e-06	9.1e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	8.26e-06	9.06e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	8.23e-06	9.02e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	8.23e-06	9.02e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	8.2e-06	8.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	8.18e-06	8.96e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	8.12e-06	8.9e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—EP300—hematologic cancer	8.11e-06	8.89e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	8.1e-06	8.88e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	8.1e-06	8.87e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—hematologic cancer	8.09e-06	8.86e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	8.08e-06	8.86e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	8.05e-06	8.82e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	7.99e-06	8.76e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	7.88e-06	8.64e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	7.87e-06	8.62e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	7.85e-06	8.61e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	7.72e-06	8.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	7.72e-06	8.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	7.67e-06	8.4e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	7.64e-06	8.37e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	7.63e-06	8.36e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	7.61e-06	8.34e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	7.59e-06	8.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	7.57e-06	8.29e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—hematologic cancer	7.55e-06	8.28e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	7.52e-06	8.24e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	7.51e-06	8.23e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	7.44e-06	8.16e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	7.42e-06	8.14e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	7.36e-06	8.07e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	7.35e-06	8.05e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	7.34e-06	8.04e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	7.26e-06	7.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	7.24e-06	7.93e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	7.12e-06	7.81e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	7.11e-06	7.79e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	7.06e-06	7.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	7.04e-06	7.71e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	6.95e-06	7.62e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	6.93e-06	7.6e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—hematologic cancer	6.91e-06	7.57e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	6.9e-06	7.56e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	6.87e-06	7.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	6.87e-06	7.53e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	6.81e-06	7.46e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	6.79e-06	7.44e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	6.78e-06	7.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	6.68e-06	7.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	6.68e-06	7.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	6.59e-06	7.23e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—EP300—hematologic cancer	6.59e-06	7.22e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	6.5e-06	7.13e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	6.42e-06	7.04e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	6.38e-06	6.99e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	6.36e-06	6.97e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	6.34e-06	6.95e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	6.32e-06	6.93e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	6.31e-06	6.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	6.27e-06	6.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	6.2e-06	6.8e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	6.15e-06	6.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	6.14e-06	6.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	6.11e-06	6.69e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	6.07e-06	6.66e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	6e-06	6.57e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	5.98e-06	6.56e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	5.97e-06	6.54e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	5.91e-06	6.47e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	5.89e-06	6.46e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	5.84e-06	6.4e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	5.79e-06	6.34e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	5.77e-06	6.33e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	5.65e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	5.63e-06	6.17e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	5.51e-06	6.04e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	5.46e-06	5.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	5.37e-06	5.88e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	5.35e-06	5.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	5.22e-06	5.72e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	5.19e-06	5.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	5.16e-06	5.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	5.15e-06	5.65e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	5.01e-06	5.5e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	4.97e-06	5.44e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	4.93e-06	5.41e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—hematologic cancer	4.9e-06	5.37e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	4.87e-06	5.34e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	4.85e-06	5.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	4.8e-06	5.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	4.79e-06	5.25e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	4.75e-06	5.21e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	4.64e-06	5.09e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	4.44e-06	4.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	4.43e-06	4.86e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	4.39e-06	4.81e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	4.1e-06	4.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	4.07e-06	4.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—hematologic cancer	3.98e-06	4.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	3.94e-06	4.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	3.77e-06	4.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	3.61e-06	3.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	3.33e-06	3.65e-05	CbGpPWpGaD
